A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT ID: NCT06525636
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
24 participants
INTERVENTIONAL
2024-10-09
2028-05-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part I: Cohort 1
Low Dose, single dose of KK8123
KK8123
Subcutaneous administration
Part I: Cohort 2
Mild dose, multiple doses of KK8123
KK8123
Subcutaneous administration
Part I: Cohort 3
High dose, multiple doses of KK8123
KK8123
Subcutaneous administration
Part I: Cohort 4
Optional, multiple doses of KK8123
KK8123
Subcutaneous administration
Part 2: Extension Period
High dose, multiple doses as confirmed for Cohort 3 of KK8123.
KK8123
Subcutaneous administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KK8123
Subcutaneous administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight is at least 40 kg.
3. Diagnosed with XLH (as documented by the investigator).
4. Have a value of fasting serum phosphorus \< 2.5 mg/dL (0.81 mmol/L) at Screening.
5. Have a value of renal TmP/GFR \< 2.5 mg/dL (0.81 mmol/L) at Screening.
6. eGFR ≥ 60 mL/min (using the Chronic Kidney Disease Epidemiology Collaboration equation \[Inker, 2021\]) at Screening.
7. Have a corrected serum calcium level \< 10.8 mg/dL (2.7 mmol/L) at Screening.
8. Provide a signed ICF.
9. Agree not to change diet and exercise regimen from one week prior to dosing to end of study.
10. Have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study (female participants only).
11. If taking chronic pain medications (including narcotic pain medications/opioids), must be on a stable regimen for at least 21 days prior to the Screening visit, and be willing to maintain medications at the same stable dose(s) and schedule throughout the clinical trial. The dose must not exceed 60 mg oral morphine equivalents/day.
12. Be willing to use a method of contraception following local country guidelines while participating in the study and for 5 months after the last dose (all sexually active participants of childbearing potential).
Women of non-childbearing potential are defined as permanently sterile (i.e., due to tubal ligation at least one year before Screening, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as at least 12 months post cessation of menses without an alternative medical cause).
Postmenopausal status of female participants will be confirmed with a Screening serum follicle-stimulating hormone level \>40 mIU/mL.
13. Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with the assessments.
1. Completion of relevant cohort in Part 1 of the study.
2. Provide a signed informed consent after the nature of Part 2 of the study has been explained.
3. Body weight is at least 40 kg.
4. Negative pregnancy test at Week 0 of Part 2 and willing to have additional pregnancy tests until the end of the study (female participants only).
5. If taking chronic pain medications (including narcotic pain medications/opioids), must be on a stable regimen for at least 21 days prior to Week 0 of Part 2, and be willing to maintain medications at the same stable dose(s) and schedule throughout the study. The dose must not exceed 60 mg oral morphine equivalents/day.
6. Be willing to use a method of contraception following local country guidelines while participating in the study and for 5 months after the last dose (all sexually active participants of childbearing potential). Women of non-childbearing potential are defined as permanently sterile (i.e., due to tubal ligation at least one year before Screening, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as at least 12 months post cessation of menses without an alternative medical cause). Postmenopausal status of female participants will be confirmed with a Week 0 serum follicle-stimulating hormone level \>40 mIU/mL.
7. Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with all the assessments.
Exclusion Criteria
2. Prior history of positive test for human immunodeficiency virus antibody, positive test for hepatitis B surface antigen, and/or hepatitis C virus antibody at Screening.
3. History of hypersensitivity to any ingredient of any therapeutic monoclonal antibody.
4. Have an active infection.
5. Grade 3 or greater nephrocalcinosis as confirmed by renal ultrasound.
6. Uncontrolled diabetes mellitus at Screening.
7. History of known immunodeficiency.
8. History of alcoholism or drug abuse.
9. History of donation of blood within 60 days prior to Screening.
10. Use of any IP or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
11. Use of any therapeutic mAb within 90 days prior to Screening.
12. Use of pharmacologically active vitamin D, its metabolites or analogs, oral phosphate for treatment of XLH, aluminum hydroxide antacids, acetazolamide, thiazide diuretics, and/or systemic corticosteroids within 14 days prior to Screening. If the participant takes any of these medications, a washout period of 14 days will be required after signing the ICF and before any other screeening assessments begin.
13. Use of medication to suppress PTH (e.g., calcimimetics) within 2 months prior to Screening and for the duration of the study.
14. Use of denosumab within 6 months prior to Screening.
15. Use of oral bisphosphonates in the 2 years prior to Screening.
16. Use of teriparatide or abaloparatide in the 2 months prior to Screening.
17. Plasma iPTH ≥ 2.5 × ULN at Screening.
18. Planned or recommended orthopedic surgery during the study.
19. History of traumatic fracture or orthopedic surgery within 6 months prior to Screening.
20. Participants who are lactating.
21. Current active and symptomatic COVID-19 infection at Day -1.
22. Presence or history of any condition that, in the view of the investigator, places the participant at high risk of poor treatment compliance or of not completing the study, or that would confound safety or interpretation of results.
1. Use of burosumab following completion of Part 1 of the study.
2. Have an active infection.
3. Donation of blood within 60 days prior to Week 0 of Part 2.
4. Use of any investigational product other than KK8123, or investigational medical device, within 30 days prior to Week 0 of Part 2, or requirement for any investigational agent prior to completion of all scheduled study assessments.
5. Use of any therapeutic mAb other than KK8123 within 90 days prior to Week 0 of Part 2.
6. Use of pharmacologically active vitamin D, its metabolites or analogs, oral phosphate for treatment of XLH, aluminum hydroxide antacids, acetazolamide, thiazide diuretics, and/or systemic corticosteroids within 14 days prior to Week 0 of Part 2.
7. Use of medication to suppress PTH (e.g., calcimimetics) within 2 months prior to Week 0 of Part 2.
8. Use of oral bisphosphonates following completion of Part 1 of the study.
9. Use of teriparatide or abaloparatide in the 2 months prior to Week 0 of Part 2.
10. Planned or recommended orthopedic surgery during the study.
11. History of traumatic fracture or orthopedic surgery within 6 months prior to Week 0 of Part 2.
12. Participants who are lactating.
13. Current active and symptomatic COVID-19 infection, or a history of suffering any long-term sequalae from COVID-19 infection.
14. Presence or history of any condition that, in the view of the investigator, places the participant at high risk of poor treatment compliance or of not completing the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyowa Kirin, Inc.
INDUSTRY
Kyowa Kirin Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyowa Kirin
Role: STUDY_CHAIR
Kyowa Kirin, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California - San Francisco
San Francisco, California, United States
Yale Center for XLH/ Yale University School of Medicine
New Haven, Connecticut, United States
Indiana University School of Medicine University Hospital
Indianapolis, Indiana, United States
Mayo Clinic
Rochester, Minnesota, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Hoptial Bictre
Le Kremlin-Bicêtre, Paris, France
Institute of Osteology and Biomechanics (IOBM)
Hamburg, , Germany
Universitaetsklinikum Wurzburg
Würzburg, , Germany
Hospital Universitario La Paz
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Farzana Perwad
Role: primary
Elizabeth Olear, MS, MA
Role: primary
Fridah Mbatia
Role: primary
Margo Black, MSN RN CCRP
Role: primary
Guilaine Guiose
Role: primary
Alison Schoen
Role: primary
Jasmin Baumann
Role: primary
Darío Aguilar Rico
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8123-001
Identifier Type: -
Identifier Source: org_study_id